Business
Anteris is developing DurAVR transcatheter aortic valve replacement technology and sells ADAPT tissue products.
Anteris revenue fell, losses and cash burn worsened, equity turned slightly negative, and Altman-Z was distressed.
The read at a glance✓ Audited against SEC data
- Business mix — DurAVR valve and ADAPT tissueNote
- Revenue — Revenue fell 29.2%Watch
- Losses — Net loss widened to $94.1MWatch
- Cash — FCF fell to -$79.8MWatch
- Balance sheet — Equity turned negativeWatch
- Insiders — 1 buy / 0 sells; $28.8M boughtOK
- Accounting — Altman-Z distress; EQ greyWatch
Where the revenue comes from
Fiscal 2025, as Anteris Technologies Global Corp. reports it. History and quarterly detail are in the app.
- ADAPT Tissue Products$1.9M
Leadership changes
From Anteris Technologies Global Corp.'s own filings, the day they're filed.
- Gregory Moss · Director · appointment
- David Roberts · President · appointment
- David St Denis · President · appointment
Latest filings
- 8-K · Company announcement2026-08-12
- 10-Q · Quarterly report2026-08-11
- 8-K · Company announcement2026-08-03
- 8-K · Company announcement2026-07-31
- 8-K · Company announcement2026-05-22
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Anteris Technologies Global Corp., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.